Good practices in the prescription of benzodiazepines and other sedative hypnotics

Tchern Kuang Lambert Low¹,², MBBS, MRCPsych, Chau Sian Lim²,³, MBBS, MMed, Cheng Lee¹,², MBBS, MMed,

¹National Addictions Management Programme, Institute of Mental Health, ²Section of Addiction Psychiatry, College of Psychiatrists, ³Department of Psychological Medicine, Changi General Hospital, Singapore

Correspondence: Dr Low Tchern Kuang Lambert, Consultant, National Addiction Management Service, Institute of Mental Health, 10 Buangkok Green Medical Park Block 9, Singapore 539747. lambert_tk_low@imh.com.sg

Singapore Med J 2021, 1–3
https://doi.org/10.11622/smedj.2021232
Published ahead of print: 15 December 2021

Online version can be found at http://www.smj.org.sg/online-first
Dear Sir,

Since the publication of the Ministry of Health’s Clinical Practice Guidelines ‘Prescribing of Benzodiazepines’\textsuperscript{(1)} and ‘Administrative Guidelines in Insomnia’\textsuperscript{(2)} in 2008, there has not been any further update or local official guideline on this pertinent issue. Benzodiazepines and other sedative hypnotics are addictive and have adverse side effects.

To promote safe and responsible prescription, the Section of Addiction Psychiatry of the College of Psychiatrists, Singapore, and the National Addictions Management Service, Singapore, have worked together to produce the following set of good practice recommendations. It is a consensus among professionals working together in the field of addictions and presents a working set of recommendations for general practitioners (GPs) and non-psychiatrists working in Singapore.

1. Benzodiazepines and ‘Z-hypnotics’ (e.g. zolpidem, zopiclone) should not be used as first-line agents for the management of insomnia. GPs should discuss sleep hygiene\textsuperscript{(3)} with patients.

2. A course of sedating antihistamines, melatonin or sedating antidepressants may be considered. The side effects of such medication need to be discussed with patients.\textsuperscript{(4)} It is recommended that their use be limited to a short course (2–4 weeks).

3. A short (2–4-week) course of benzodiazepines may be considered for acute insomnia. Shorter-acting benzodiazepines (e.g. alprazolam) have a higher addictive potential than longer-acting ones.\textsuperscript{(5)} However, longer-acting benzodiazepines may cause daytime sedation. As such, their risks and benefits should be considered.

4. Patients with acute insomnia should not be prescribed more than one type of sedative hypnotic.
The mainstay of treatment for chronic insomnia is cognitive behavioural therapy for insomnia (CBT-I), and patients should be referred for professional help with a psychologist trained in CBT-I.

Patients with chronic (> 3 months) insomnia should be referred to a specialist for thorough evaluation.

For patients with chronic insomnia who are already on benzodiazepine or ‘Z-hypnotics’ for many years, dosage reduction should be considered. These patients should be referred to psychiatrists, as they could be dependent on such drugs.

Benzodiazepines should not be the first line of treatment for anxiety disorders and should not be prescribed as monotherapy for anxiety disorders.

When prescribed for severe anxiety, benzodiazepines should be prescribed at their lowest effective dose for the shortest period of time, and should be avoided if the anxiety is mild.

Dosage of benzodiazepines and ‘Z-hypnotics’ should be reduced in the elderly (> 65 years old).

Benzodiazepines and ‘Z-hypnotics’ should generally not be prescribed to patients with substance use disorders.

The risk of developing dependence and long-term side effects of benzodiazepines and ‘Z-hypnotics’ should be discussed with patients and documented.

Yours sincerely,

Tchern Kuang Lambert Low, Chau Sian Lim, Cheng Lee

1 National Addictions Management Programme, Institute of Mental Health, 2 Section of Addiction Psychiatry, College of Psychiatrists, 3 Department of Psychological Medicine, Changi General Hospital, Singapore. lambert_tk_low@imh.com.sg
REFERENCES


